Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Erem C;Erem C; Kocak M; Hacihasanoglu A; Yilmaz M
  • Source:
    Journal of endocrinological investigation [J Endocrinol Invest] 2008 Jun; Vol. 31 (6), pp. 537-41.
  • Publication Type:
    Comparative Study; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print Cited Medium: Internet ISSN: 1720-8386 (Electronic) Linking ISSN: 03914097 NLM ISO Abbreviation: J Endocrinol Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Berlin : Springer
      Original Publication: Milano, Published for the Italian Society of Endocrinology by Editrice Kurtis.
    • Subject Terms:
    • Abstract:
      Background and Objectives: In men, androgens have both pro- and anti-thrombotic effects. Androgen deficiency in men is associated with an increased incidence of cardiovascular disease (CVD). However, the influence of hypogonadism on hemostasis is controversial. Little is known about hemostatic features of male patients with idiopathic hypogonadotropic hypogonadism (IHH). Thus, the aim of the present study was to evaluate the markers of endogenous coagulation and fibrinolysis, and to investigate the relationships between endogenous sex hormones and hemostatic parameters and serum lipid profile in men with IHH.
      Design and Methods: Seventeen patients with IHH and 20 age-matched healthy controls were included in the study. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factors (F) V, VII, VIII, IX, and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA), and tissue plasminogen activator inhibitor (PAI-1), as well as common lipid variables, were measured. The relationships between serum sex hormones and these hemostatic parameters were examined.
      Results: Compared with the control subjects, platelet count, FV, FX, and protein C activities were significantly increased in patients with IHH (p<0.01, p<0.05, p<0.01, and p<0.05, respectively), whereas AT III was decreased (p<0.05). Fibrinogen, FVIII, vWF, t-PA, PAI-1, and the other coagulation/fibrinolysis parameters and lipid profile in patients with IHH were not different from the controls. In patients with IHH, we showed that serum LH level was negatively correlated with fibrinogen (r: -0.78, p<0.01) and protein C (r: -0.55, p<0.05) and positively correlated with t-PA (r: 0.53, p<0.05). Serum FSH levels inversely correlated with fibrinogen (r: -0.75, p<0.01).
      Interpretation and Conclusions: We found some differences in the hemostatic parameters between the patients with IHH and healthy controls. Increased platelet count, FV and FX activities and decreased AT III levels in patients with IHH represent a potential hypercoagulable state, which might augment the risk for atherosclerotic and atherothrombotic complications. Therefore, IHH may be associated with an increased risk of CVD. However, sex hormones may play a role at different levels of the complex hemostatic system in patients with IHH.
    • References:
      Metabolism. 1989 Oct;38(10):1010-5. (PMID: 2507874)
      Int J Biochem Cell Biol. 2004 Mar;36(3):386-9. (PMID: 14687916)
      Maturitas. 1996 Jul;24(3):147-55. (PMID: 8844628)
      Am J Physiol. 1977 Apr;232(4):H381-5. (PMID: 851202)
      Metabolism. 1997 Nov;46(11):1287-93. (PMID: 9361687)
      Blood Cells Mol Dis. 2006 Mar-Apr;36(2):211-6. (PMID: 16464623)
      Coron Artery Dis. 2003 Jun;14(4):285-91. (PMID: 12826927)
      FEBS Lett. 2005 Jun 13;579(15):3310-6. (PMID: 15943976)
      Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):749-54. (PMID: 8640402)
      Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):530-8. (PMID: 11950687)
      Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):801-8. (PMID: 7573247)
      Kidney Int. 2001 Sep;60(3):1009-17. (PMID: 11532095)
      Eur J Endocrinol. 2005 Feb;152(2):285-91. (PMID: 15745938)
      J Vet Med A Physiol Pathol Clin Med. 2005 Nov;52(9):436-9. (PMID: 16268953)
      Cardiovasc Drug Rev. 2002 Fall;20(3):175-98. (PMID: 12397366)
      Br J Haematol. 1994 May;87(1):205-8. (PMID: 7947249)
      Int J Biochem Cell Biol. 2004 Aug;36(8):1393-9. (PMID: 15147718)
      Atherosclerosis. 1988 May;71(1):71-6. (PMID: 3377881)
      Contraception. 1995 Aug;52(2):115-9. (PMID: 8536448)
      Arterioscler Thromb. 1993 Apr;13(4):467-71. (PMID: 8466882)
      Circulation. 1999 Aug 17;100(7):736-42. (PMID: 10449696)
      Thromb Haemost. 1997 Jul;78(1):339-43. (PMID: 9198176)
      Thromb Res. 1982 Nov 1;28(3):423-5. (PMID: 7179226)
      Arterioscler Thromb. 1994 Nov;14(11):1737-40. (PMID: 7947597)
      J Lab Clin Med. 1993 Oct;122(4):412-20. (PMID: 8228555)
      J Lab Clin Med. 1995 Mar;125(3):326-33. (PMID: 7897299)
      Lancet. 1962 Jul 21;2(7247):128-32. (PMID: 13891922)
      Arterioscler Thromb. 1991 Jan-Feb;11(1):183-90. (PMID: 1670989)
      Thromb Res. 1987 Mar 15;45(6):719-28. (PMID: 3590099)
      FEBS Lett. 2002 Jul 17;523(1-3):85-9. (PMID: 12123809)
      J Lab Clin Med. 1982 Feb;99(2):247-53. (PMID: 7061919)
      Arterioscler Thromb. 1994 May;14(5):701-6. (PMID: 8172848)
      Atherosclerosis. 1993 Feb;99(1):55-61. (PMID: 8461060)
      Am J Clin Nutr. 1997 May;65(5 Suppl):1674S-1682S. (PMID: 9129509)
      J Clin Endocrinol Metab. 1995 Jun;80(6):1794-8. (PMID: 7775625)
      Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2317-20. (PMID: 1532256)
      Blood Coagul Fibrinolysis. 2002 Dec;13(8):657-70. (PMID: 12441904)
      Am J Hematol. 2006 Feb;81(2):95-100. (PMID: 16432848)
    • Accession Number:
      0 (Biomarkers)
      9000-94-6 (Antithrombin III)
      9001-24-5 (Factor V)
      9001-29-0 (Factor X)
    • Publication Date:
      Date Created: 20080702 Date Completed: 20090205 Latest Revision: 20211020
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/BF03346404
    • Accession Number:
      18591887